Lenalidomide is active for extramedullary disease in refractory multiple myeloma

Author： Nakazato Tomonori Mihara Ai Ito Chisako Sanada Yukinari Aisa Yoshinobu

ISSN： 0939-5555

Source： Annals of Hematology, Vol.91, Iss.3, 2012-03, pp. : 473-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)

By Wang M. Delasalle K. Giralt S. Alexanian R.

Hematology, Vol. 15, Iss. 2, 2010-04 ,pp. : 70-73

Maney Publishing

Access to resources Recommend Favorite

Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma

By Serefhanoglu Songul

Annals of Hematology, Vol. 87, Iss. 10, 2008-10 ,pp. : 853-854

Springer Publishing Company

Access to resources Recommend Favorite

Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone

By Shahan Jaime

International Journal of Hematology, Vol. 96, Iss. 6, 2012-12 ,pp. : 818-819

Springer Publishing Company

Access to resources Recommend Favorite

Co-existing chronic myeloid leukaemia and multiple myeloma: rapid response to lenalidomide during imatinib treatment

By Offiah C.

International Journal of Hematology, Vol. 95, Iss. 4, 2012-04 ,pp. : 451-452

Springer Publishing Company

Access to resources Recommend Favorite

Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma

By Harada Takeshi

International Journal of Hematology, Vol. 97, Iss. 6, 2013-06 ,pp. : 743-748

Springer Publishing Company

Access to resources Recommend Favorite